Skip to content

Effects of Selenium Towards Type 2 Diabetes

Effects of Selenium Nutritional Supplement of Glucose, Nutritional Status, and Clinical Outcome Among Type 2 Diabetes Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06457984
Enrollment
300
Registered
2024-06-13
Start date
2024-06-15
Completion date
2025-05-07
Last updated
2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

selenium, intervention, glucose, nutritional status, clinical outcome

Brief summary

According to the prevalence of non-communicable chronic diseases and aging population characteristics, this study is exploring the coexist effects combined with various dimensions: nutritional functions, metabolic homeostasis, inflammation and immunity by the selenium supplementation among type 2 diabetes, which based on insulin resistance, beta-cell function disorders, and body metabolic homeostasis disorders of the mechanism of type 2 diabetes by lifecycle so that could provide with a totally new and safe nutritional method for type 2 diabetes prevention and diagnosis.

Detailed description

This study will last 16 weeks. There will be 300 subjects enrolled by random lottery methods in this randomized double-blind placebo-controlled clinical study by control group, low dose group and high dose group. During the study processing, follow-up visit by call, questionnaires, blood and stool collection, and functional testing will appear. Statistical analysis would be analysis according to the actual outcome of study.

Interventions

DIETARY_SUPPLEMENTSelenium nutritional supplementation

Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Double(Participant, Investigator)

Intervention model description

Parallel Assignment

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

.Range of age:18\ 75, both males and females are permitted. .As to the diagnosis criteria of type 2 diabetes:glucose higher than 13.9mmol/L, drastic fluctuation (upper that 2mmol/L) , severe complication, or coupled with other severe chronic diseases( including overweight, obesity, lipid disorders, hypertension, ASCVD,HF, CKD, never appears. .Treatments: exercise lifestyle intervention plus oral antidiabetic drugs, such as: single drug(metformin) plus exercise lifestyle intervention, coupled drugs(metformin+acarbose) plus exercise lifestyle intervention, both of them never use insulin. .Signed with the informed consent, and enrolled in this study in volunteer.

Exclusion criteria

.Physical fitness must attach to the goal of Par-Q questionnaire and 6 minutes running test. Besides, individuals whose glucose has drastic fluctuation should be excluded. .Coexist with severe complication and being in the urgent status during the progress of diseases, such as acute complication and infection, hyperplasia retinopathy, severe neuropathy, diabetic foot ulcer, coupled with cardiac insufficiency, diabetic massive proteinuria, recent myocardial infarction, cerebral infarction or cerebral hemorrhage, blood glucose higher than 13.9mmol/L or less than 3.9 mmol/L. * Patients suffering various serious chronic diseases, including unstable angina, uncontrolled arrhythmia, severe valvular heart disease or cardiomyopathy; * Uncontrolled hypertension or blood pressure over 180/110mmHg; .In the period of trying to conceive or pregnant or lactating. .Patients who have had cerebral infarction, stroke, history of major surgery, acute attack of infectious diseases or obvious sequelae of infection; .Sever psychology disorders and mental diseases. * The mass of selenium in body is over the upper limitation, or selenium yeast tablets, as a nutrition supplemented, subjects should not allergic to yeast, and cannot be included. Besides, patients who have recently taken selenium-rich health food or medicine; * Severe malnutrition and overnutrition; * Significant mobility and cognitive impairment; .Sickle cell disease, hemodialysis, recent blood loss or blood transfusion, etc.

Design outcomes

Primary

MeasureTime frameDescription
Drugs of reduce glucose or stop using the antidiabetics.12 weeksDose or types of antidiabetics drugs would reduce.

Secondary

MeasureTime frameDescription
Status of immunity12 weeksLevel of immunity indicator serum iron would increase along with the supplementation of selenium
Situation of glucose12 weeksLevel of glucose would decrease alone with the supplementation of selenium
Nutrition status of selenium12 weeksContent of selenium in serum would increase alone with the supplementation of selenium
GPX activity12 weeksLevel of GPX-1 activity would decrease alone with the supplementation of selenium

Countries

China

Contacts

Primary Contactyu kang, MD
yuk1997@sina.com+86 13801130457
Backup ContactLi Yanping, PhD
1204571005@qq.com+86 13430273762

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026